We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antibiotic stewardship program in Intensive Care Unit: First report from Iran.
- Authors
Vahidi, Ghoncheh; Mohammadi, Mostafa; Shojaei, Lida; Ramezani, Masoud; Jafari, Sirus; Khalili, Hossein
- Abstract
Introduction: Few data regarding antibiotic stewardship programs in critically ill patients are available. In the present study, the consequence of changing an empirical antibiotic regimen from a carbapenem (meropenem) to a noncarbapenem antibiotic (piperacillin-tazobactam) was evaluated in critically ill patients with a suspicion of sepsis. Methods: This open-label randomized clinical trial was conducted during May 2015-January 2017 at the general Intensive Care Unit of the Imam Khomeini Hospital Complex, Tehran, Iran. In this study, a carbapenem (meropenem) or a noncarbapenem (piperacillin-tazobactam) antibiotic was considered as an empirical antibiotic regimen in 100 critically ill patients with a suspicion of sepsis. Clinical response and bacterial eradication were defined as primary and secondary outcomes of the study, respectively. Chi-square, Mann-Whitney, and independent sample t-tests were used for comparing variables between the groups. ANOVA was used to compare changes in the mean differences of parameters between the groups. Meaningful difference was indicated as P = 0.05. Results: During the first 72 h of the antibiotic course, the number of patients with clinical response was comparable between piperacillin-tazobactam and meropenem groups (21 [42%] and 25 [50%], respectively, P = 0.31). Also, at this time, microbial eradication occurred in 13 (54.16%) and 9 (40.90%) patients in piperacillin-tazobactam and meropenem groups, respectively (P = 0.67). Conclusions: Using a carbapenem (meropenem) instead of a noncarbapenem (piperacillin-tazobactam) as an empirical antibiotic regimen did not affect clinical response and bacterial eradication rates in critically ill patients with a suspicion of sepsis.
- Subjects
ANTIBIOTICS; MEROPENEM; INTENSIVE care patients
- Publication
International Journal of Critical Illness & Injury Science, 2018, Vol 8, Issue 2, p83
- ISSN
2229-5151
- Publication type
Article
- DOI
10.4103/IJCIIS.IJCIIS_10_18